Research using functional neuroimaging techniques has confirmed that the anti-obesity activity of the GLP-1 E2 dual agonist occurs through interactions with co-expressed receptors in brain areas that regulate homeostatic eating behavior and reward. The gene discussed is GCG; the disease is obesity disorder.